GV20 Therapeutics Announces Oral Presentation on GV20-0251 for Solid Tumors Targeting IGSF8 at AACR Annual Meeting 2024

GV20 Therapeutics announced that its abstract was selected for an oral presentation at the American Association of Cancer Research Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, CA.

CAMBRIDGE, Mass., March 5, 2024 /PRNewswire/ -- GV20 Therapeutics, a clinical-stage biotechnology company integrating AI, genomics, and disease biology to create next-generation antibody therapeutics for cancer, announced today that its abstract was selected for an oral presentation at the American Association of Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, CA.

Details of the oral presentation are below:

Title:IGSF8 is a novel innate immune checkpoint and cancer immunotherapy target
Session Type: Minisymposium
Session Category: Immunology
Session Title: Immune Targets and Therapies
Session Date/Time: Monday Apr 8, 2024, 2:30 PM - 4:30 PM
Abstract Presentation Number: 3914

More information can be found on the 2024 AACR website.

ABOUT GV20 THERAPEUTICS

At GV20 Therapeutics, our mission is to develop a differentiated pipeline of innovative antibody therapeutics to transform the treatment of cancer. We leverage our in-house STEAD platform (Simultaneous Target Evaluation and Antibody Discovery), which integrates AI, genomics, and disease biology to identify novel drug targets and create next-generation therapies against these targets. Our lead program, GV20-0251, a first-in-class, fully human, Fc-attenuated IgG1 monoclonal antibody targeting IGSF8, is in a multi-center Phase I clinical trial in patients with advanced solid tumors (NCT05669430). GV20 is headquartered in Cambridge, MA.

To learn more about GV20, please visit https://gv20tx.com/ and follow the company on LinkedIn.

Business Contact
Ying Gong, Ph.D., CBO
BD@gv20tx.com

Investor and Media Contact
Amy Conrad
Juniper Point
amy@juniper-point.com

GV20 Therapeutics logo

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/gv20-therapeutics-announces-oral-presentation-on-gv20-0251-for-solid-tumors-targeting-igsf8-at-aacr-annual-meeting-2024-302080249.html

SOURCE GV20 Therapeutics

MORE ON THIS TOPIC